The candidate in question, dubbed AZD0780, is an oral small molecule PCSK9 inhibitor in development for dyslipidemia, a condition characterized by elevated cholesterol in the blood that can ...

The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the victor.

这篇综述聚焦 Tafolecimab，它是针对 PCSK9 的全人源单克隆抗体。文中指出，其能有效降低低密度脂蛋白胆固醇（LDL-C）水平，改善脂蛋白 (a)[Lp (a)] 等其他脂质参数，安全性良好，长效剂型可提高用药依从性，在降脂治疗领域意义重大。 Tafolecimab：降脂领域的新星 ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

2500.HK Venus Medtech (Hangzhou) Inc.

Tourmaline Bio's Pacibekitug shows promise in IL-6 targeting for autoimmune diseases. Learn about its potential and ongoing trials. Read why TRML is a hold.

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercializati ...

Coronary artery disease has long been understood through the paradigm of epicardial coronary artery obstruction, causing ...

Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization.

上述模型清晰解释了LDL受体如何进入细胞，但是进入细胞内的LDL受体如何返回细胞表面尚不清楚。 PCSK9是肝脏分泌因子，人类遗传学研究发现其功能失活突变显著降低血清胆固醇水平，降低冠心病发病率80%以上，且PCSK9基因缺失个体身体健康2-4。这些证据快速 ...

China’s first domestically produced and independently developed anti-PD-1 monoclonal antibody. Toripalimab has been approved in over 35 countries and regions including China, the US, and Europe.